1Bezerra DP, Pessoa C, de Moraes MO, et al. Overview of the thera- peutic potential of piplartine (piperlongumine) [J]. Eur J Pharm Sci, 2013, 48(3): 453-463.
2Liu JM, Pan F, Li L, et al. Piperlongumine selectively kills glioblas- toma multiforme cells via reactive oxygen species accumulation de- pendent JNK and p38 activation [J]. Biochem Biophys Res Com- mun, 2013, 437(1): 87-93.
3Hall SS, Son D J, Yun H, et al. Ppedongumine inhibits proliferation and survival of Burkitt lymphoma in vitro [J]. Leuk Res, 2013, 37 (2): 146-154.
4Randhawa H, Kibble K, Zeng H, et al. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine [J]. Tox- icol In Vitro, 2013, 27(6): 1626-1633.
5Gong LH, Chen XX, Wang H, et al. Piperlongumine Induces apopto-sis and synergizes with cisplatin or paclitaxel in human ovarian can- cer cells [J]. Oxid Med Cell Longev, 2014, 2014: 906804.
6Ginzburg S, Golovine KV, Maldaov PB, et al. Piperlongumine inhib- its NF-KB activity and attenuates aggressive growth characteristics of prostate cancer cells [J]. Prostate, 2014, 74(2): 177-186.
7Golovine KV, Makhov PB, Teper E, et al. Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells [J]. Prostate, 2013, 73(1): 23-30.
8Shrivastava S, Kulkami P, Thummuri D, et al. Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to in- duce caspase-dependent apoptosis in human triple-negative breast cancer cells [J]. Apoptosis, 2014, 19(7): 1148-1164.
9Pei S, Minlaajuddin M, Callahan KP, et al. Targeting aberrant gluta- thione metabolism to eradicate human acute myelogenous leukemia cells [J]. J Biol Claem, 2013, 288(47): 33542-33558.
10Bezerra DP, Pessoa C, Moraes MO, et al. In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species [J]. J Appl Toxicol, 2008, 28(5): 599-607.
